Introduction

The past four decades have seen significant progress in the understanding, diagnosis, treatment, and prevention of cancer. However, as cancer mortality rates have declined in the U.S. and other developed countries, cancer incidence and mortality continue to rise around the world. The latest World Health Organization (WHO) statistics predicted 13.2 million cancer-related deaths worldwide by 2030, which is up from 7.6 million in 2008 when the last report was published. With the continuing growth and aging of the world’s population, the global burden of new cancer cases is estimated to rise from 12.7 million in 2008 to 20.3 million by 20301,2.

The causes of the predicted increase in the global cancer burden are numerous and relatively well established. In addition to aging, these include: lifestyle risk factors such as tobacco use, diet and obesity, lack of exercise, alcohol consumption, and excessive exposure to sunlight; environmental and occupational exposures to carcinogens and mutagens (including chemicals and radiation); infectious agents (Helicobacter pylori, hepatitis B virus, hepatitis C virus, human papillomavirus, Epstein-Barr virus); chronic inflammation; hormone metabolism; family history; and ethnicity and socioeconomic status.

The American Association for Cancer Research (AACR) believes that the conquest of cancer, through further scientific progress in cancer etiology, prevention, diagnosis, treatment, and quality healthcare delivery, must become an international priority. There is no doubt that the looming global cancer crisis requires global solutions. It is our conviction that, by working collaboratively with governments around the world, relevant institutions, and key individual stakeholders in the cancer field, we have the potential to develop innovative approaches that will be effective in expediting advances against cancer and save more lives from this disease.

Progress against cancer

The realization that gene damage and genetic mutations can cause cancer was arguably one of the greatest research advances in the modern era, one that paved the way for therapies that target specific cancer-driving defects. During the 1970s, scientists identified two families of genes—proto-oncogenes
and tumor suppressor genes—that normally regulate the natural processes of cell growth and death in healthy tissues and organs. Oncogenes, the mutated form of proto-oncogenes, encode faulty proteins involved in the genesis and spread of tumors. Tumor suppressor genes typically control molecular programs that negatively regulate cell proliferation. When their gatekeeper role is altered by mutations, cell growth and proliferation goes awry. Further research subsequently established that tumors are more than insular masses of proliferating cancer cells. It also quickly became clear that the contributions of the tumor microenvironment greatly influenced tumorigenesis. Therefore, tumors should be viewed as complex tissues composed of multiple distinct cell types interacting with one another. In 2000, Hanahan and Weinberg proposed the concept of cancer “hallmarks”: six essential capabilities that normal cells acquire as they evolve progressively to a neoplastic state. This conceptual framework, which was largely vindicated by subsequent discoveries over the last decade, was recently revisited and expanded.

In this paper, we review a few of the most recent breakthroughs that are fueling medical advances and bringing new hope for patients affected by this devastating disease.

The last ten years have seen remarkable progress in cancer research, aided by technological advances such as the so-called “next-generation sequencing” (NGS). Thanks to large-scale collaborative efforts such as the “International Cancer Genomics Consortium” (ICGC), as well as other initiatives, we now have an ever-increasing understanding of the genes and molecular pathways that are disrupted in cancer. This knowledge has yielded a cornucopia of new therapies based on drugs that precisely target these alterations. Molecular targeted therapies are now an integral component of cancer patient care, alongside the three pillars of cancer treatment that are surgery, radiation, and chemotherapy. Cancer genomics, while revealing a treasure trove of information about the basic biological processes that become perturbed in cancer, has also made it abundantly clear that cancer is not one disease. Tumors are extremely heterogeneous, with more than 200 different types and subtypes currently recognized. This has triggered a paradigm shift in the standard of care, away from a one-size-fits-all approach and toward individual or “tailored therapy” whereby treatment decisions are based on the mutational landscape of a patient’s tumor. This approach, commonly referred to as personalized cancer medicine or precision medicine, is still very much in early development, but it clearly represents the future of cancer care.

Challenges and opportunities

Decades of research have provided insights into the numerous factors that are germane to cancer and have shown that the majority of cancers diagnosed today are the result of preventable causes. This knowledge has been translated into new clinical approaches, as well as public education and policy initiatives. However, despite the demonstrated success of public health campaigns, convincing individuals about the importance of behavioral and lifestyle changes remains an upward battle. Nevertheless, cancer prevention and early detection continue...
to represent areas where effective strategies have the potential to yield the greatest impact on overall reduction of morbidity and mortality from this disease. Global cancer surveillance and cancer control programs must be strengthened with appropriate resources. When population-based screening programs have been implemented, they have almost invariably been met with a dramatic increase in 5-year survival for the cancers they detect. Continued research to develop new and better methods for the identification of high-risk individuals is paramount if we are to reduce the burden of a disease that is largely preventable. Risk stratification will also help address the legitimate concerns that heightened surveillance may lead to overdiagnosis and overtreatment.

Another challenge is the significant gap that persists between basic research and clinical application, despite the clear progress over the past 5 years. The enormous potential of translational cancer research will only be realized when impediments are systematically addressed. More precise diagnoses and treatments will require improved genomics-based technologies, large repositories and interactive data networks, and better mathematical and computer models to analyze and exploit the deluge of “big data” generated by large-scale systematic cancer genomics projects such as those mentioned earlier. There is also a clear need for standardized and uniform policies and guidelines for the isolation, processing, analysis, and annotation of biospecimens. The ability to implement innovative clinical trial designs will require ongoing dialogue between basic scientists and clinical researchers. Drug development advances will necessitate animal models with better predictive value, as well as continued efforts in biomarker discovery. Despite evident success, rational drug development remains a complex, high-risk, and time-consuming process that might greatly benefit from coordinated pre-competitive collaborations among all sectors in the field; from academia to government to the biotechnology and pharmaceutical industry, but also philanthropic organizations and patient advocacy groups.

Finally, advances have not been uniform for all types of cancer, or for all patients with a certain type of cancer. In addition, the burden of cancer is not evenly distributed across populations. Thus, even in developed countries, cancer remains a significant problem despite the considerable progress mentioned above. Furthermore, in low- and middle-income countries (LMIC) that are transitioning to higher levels of development, reduction in infection-related cancers is unfortunately often accompanied by an increase in cancers related to a Westernization of lifestyle. Of all major causes of disease worldwide, cancer has the greatest economic burden from premature death and disability. Its global economic toll is 20% higher than that from any other major disease. In this respect, the inclusion of cancer in the 2011 United Nations Declaration on Non-Communicable Diseases has a commitment to reduce preventable deaths by 25% by the year 2025 is not only commendable, but also highly timely.

In conclusion, we have entered a new era of pioneering breakthroughs in cancer research. Scientific opportunities to markedly reduce the global cancer burden exist today, but more resources are needed to fully realize the potential of today’s science and technology. The AACR strongly believes that research is our best defense against cancer. Continued progress against a disease that is highly heterogeneous and deceptively adaptive will require a sustained, collaborative, and global effort. This includes investing in the talent, tools, and infrastructure to support cancer research and biomedical science.

Conflict of interest statement
No potential conflicts of interest are disclosed.

References

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.
2. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol 2012;13:790-801.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674.
5. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science 2013;339:1546-1558.
6. Garraway LA, Lander ES. Lessons from the cancer genome. Cell 2013;153:17-37.
7. Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 2012; 30:2055-2062.
8. Von Hoff DD, Ervin TJ, Arena FP, Chiorean EG, Infante JR, Moore MJ, et al. Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates. J Clin Oncol 2013;31:abstr 4005.
9. Tan J, Cang S, Ma Y, Petrillo RL, Liu D. Novel histone deacetylase
inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010;3:5.

10. Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 2011;1:598-607.

11. Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol 2011;29:4828-4836.

12. John RM, Ross H. The global economic cost of cancer. Atlanta, GA: American Cancer Society and Austin, TX: Livestrong 2010.

Cite this article as: Biemar F, Foti M. Global progress against cancer—challenges and opportunities. Cancer Biol Med 2013;10:183-186. doi: 10.7497/j.issn.2095-3941.2013.04.001